## Symdeko® (tezacaftor/ivacaftor and ivacaftor) – Expanded indication

- On June 21, 2019, the FDA announced the approval of Vertex's Symdeko (tezacaftor/ivacaftor and ivacaftor), for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the *F508del* mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene that is responsive to tezacaftor/ivacaftor based on *in vitro* data and/or clinical evidence.
    - Symdeko was previously approved in patients ages 12 and older who had the same specific genetic mutations.
    - If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a *CFTR* mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
- The efficacy of Symdeko in patients age 6 to less than 12 years was extrapolated from patients age 12 years and older with support from population pharmacokinetic analyses showing similar tezacaftor and ivacaftor exposure levels in patients age 6 to less than 12 years and in patients age 12 years and older.
- The safety of Symdeko to treat cystic fibrosis patients age 6 to less than 12 years was supported by data from a study that included a 24-week, open-label treatment period with 70 cystic fibrosis patients age 6 to less than 12, and had similar observations of safety to clinical trials in age 12 and older.
- In addition to the expanded indication, the FDA also approved a new co-packaged formulation for Symdeko containing tezacaftor 50 mg/ivacaftor 75 mg fixed-dose combination tablets and ivacaftor 75 mg tablets.
    - Symdeko was previously only available as a co-packaged product containing tezacaftor 100 mg/ivacaftor 150 mg fixed-dose combination tablets and ivacaftor 150 mg tablets.
- The recommended dose for Symdeko in pediatric patients age 6 to less than 12 years weighing less than 30 kg is one tablet (containing tezacaftor 50 mg/ivacaftor 75 mg) in the morning and one tablet (containing ivacaftor 75 mg) in the evening.
- The recommended dose of Symdeko in adults and pediatric patients age 12 years and older or pediatric patients age 6 to less than 12 years weighing 30 kg or more is one tablet (containing tezacaftor 100 mg/ivacaftor 150 mg) in the morning and one tablet (containing ivacaftor 150 mg) in the evening.
- Vertex's launch plans for the new Symdeko co-packaged product are pending.